openPR Logo
Press release

Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract manufacturing market is projected to reach USD 25 billion by 2030, claims Roots Analysis

11-20-2020 05:47 AM CET | Health & Medicine

Press release from: Roots Analysis

Growing at an annualized rate of 12%, the HPAPI and cytotoxic

Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers

Roots Analysis is pleased to announce the publication of its recent study, titled, “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030.”

For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of HPAPIs and cytotoxic drugs. The study also features a detailed analysis of the key drivers and trends related to this evolving domain. In addition to other elements, the study includes:
A detailed assessment of the current market landscape of companies offering contract services for manufacturing HPAPIs and cytotoxic drugs.
A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, featuring insightful representations.
Detailed profiles of leading contract manufacturers of HPAPI and cytotoxic drugs (shortlisted on the basis of proprietary criterion).
An analysis of the partnerships that have been established in this domain, in the recent past.
An analysis of the various expansion initiatives undertaken by the players in this domain.
An estimate of the overall, installed capacity for manufacturing HPAPIs and cytotoxic drugs based on data reported by industry stakeholders in the public domain.
A qualitative analysis to decide whether to manufacture the potent products in-house or engage the services of a CMO.
A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution.
A case study on the antibody drug conjugates (ADCs) manufacturing market, highlighting a list of contract service providers and in-house manufacturers in this domain.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of Product
HPAPIs
Highly Potent Finished Dosage Forms

Company Size
Small-sized
Mid-sized
Large / Very Large

Scale of Operation
Preclinical / Clinical
Commercial

Type of Pharmacological Molecule
Small Molecules
Biologics

Type of Highly Potent Finished Dosage Form
Injectables
Oral Solids
Creams
Others
Key geographical regions
North America
Europe
Asia Pacific
Rest of the World

For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

The report includes detailed transcripts of discussions held with the following senior level representatives of stakeholder companies:
Antonella Mancuso (Vice President and Chief Operating Officer, BSP Pharmaceuticals) and Maria Elena Guadagno (Business Director, BSP Pharmaceuticals)
Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)
Kevin Rosenthal (Business Head, Formulations and Finished Products, Alphora Research)
Jennifer L Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
Roberto Margarita (Business Development Director, CordenPharma)
Allison Vavala (Senior Manager, Business Development, Helsinn)
Mark Wright (Site Head, Piramal Healthcare)
Javier E. Aznárez Araiz (Business Development Technician, Idifarma)

Key companies covered in the report
AbbVie Contract Manufacturing
CARBOGEN AMCIS
Catalent
Evonik
Formosa Laboratories
Intas
Lonza
MabPlex
Pfizer CentreOne

For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

Other Recent Offerings
1. Antibody Contract Manufacturing Market, 2020 – 2030
2. Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030
3. Biopharma Contract Manufacturing Market (3rd Edition), 2019 – 2030

Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com

Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract manufacturing market is projected to reach USD 25 billion by 2030, claims Roots Analysis here

News-ID: 2191213 • Views:

More Releases from Roots Analysis

Proteomics Market CAGR To Be 7.9% % by 2035, Due To The Growing Adoption of Proteomics Solutions| Roots Analysis
Proteomics Market CAGR To Be 7.9% % by 2035, Due To The Growing Adoption of Prot …
According to our latest market report "Proteomics Market" by Type of Offering, Type of Instrument / Technology, Type of Reagent, Type of Proteomics Service, Application Area, End-users, Type of Operation and Geography: Industry Trends and Global Forecasts, Till 2035", the global protein expression market, valued at USD 2.7 billion in 2024, is estimated to reach USD 3.0 billion in 2025 and USD 6.3 billion by 2035, representing a CAGR of
Industrial Robotics Market to Reach USD 39.03 Billion by 2035, Driven by Rising Automation Demand Across Manufacturing | Roots Analysis
Industrial Robotics Market to Reach USD 39.03 Billion by 2035, Driven by Rising …
09-04-2025 | Robotics & Automation Press release from: Roots Analysis According to Roots Analysis' latest industry report titled "Industrial Robotics Market: Industry Trends and Global Forecasts, till 2035", the global industrial robotics market is projected to grow from USD 17.64 billion in 2024 to USD 18.80 billion in 2025, reaching USD 39.03 billion by 2035 at a CAGR of 7.5% during the forecast period. To request a quote for this report, visit: https://www.rootsanalysis.com/industrial-robotics-market/request-quote Market Overview Industrial
Targeted Drug Delivery Device Market Size to reach USD 2,153 million by 2035 | Roots Analysis
Targeted Drug Delivery Device Market Size to reach USD 2,153 million by 2035 | R …
According to our latest market report "Targeted Drug Delivery Device Market" by Type of Device, Target Organ, Type of Therapy Delivered, Route of Administration, Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, Till 2035", the targeted drug delivery device market size is projected to reach USD 2,153 million by 2035 from USD 427 million in 2026, growing at a CAGR of 19.7% in the forecast period, till
The Conjugation and Labeling Services Market is projected to grow at a CAGR of 10.3%, till 2035, claims Roots Analysis
The Conjugation and Labeling Services Market is projected to grow at a CAGR of 1 …
The complexities associated with conjugation of biomolecules and the need for click-chemistry expertise have prompted the pharmaceutical industry to rely on conjugation and labeling service providers To request quote of this report, please visit: https://www.rootsanalysis.com/reports/conjugation-and-labeling-services-market/request-quote.html Roots Analysis is pleased to announce the publication of its recent study, titled, "Conjugation and Labeling Services Market, 2023-2035" The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.

All 5 Releases


More Releases for HPAPI

Cytotoxic Drugs and HPAPI Manufacturing Market
Cytotoxic Drugs and HPAPI Manufacturing Market worth $27.1 Bn by 2031 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Cytotoxic Drugs and HPAPI Manufacturing Market- (Type of Product (HPAPI and highly potent finished dosage form), Company Size (Small, Mid-sized, Large, Very Large), Scale of Operation (Preclinical, clinical, commercial), Type of Molecule (Small molecules, biologics), Type of Highly Potent
HPAPI Market Player Profiling, Forecast till 2028
According to Ameco Research 'HPAPI Market report, the analysts took this into account when estimating the HPAPI Market size and CAGR for the respective industry. The report's author has thoroughly examined the market and concluded that the HPAPI Market 's growth will level off in the coming years. In addition to that, the prominent qualitative information added in the report includes HPAPI Market trends, segmentation, key companies, SWOT, PORTER and
HPAPI Market Size Forecast till 2028
According to Ameco Research 'HPAPI Market report, the analysts took this into account when estimating the HPAPI Market size and CAGR for the respective industry. The report's author has thoroughly examined the market and concluded that the HPAPI Market 's growth will level off in the coming years. In addition to that, the prominent qualitative information added in the report includes HPAPI Market trends, segmentation, key companies, SWOT, PORTER and
HPAPI Market: Opportunities and Challenges
The global HPAPIs Market is projected to register a CAGR of 8.7% during the forecast period (2018-23). The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies and growing focus on precision medicine. However, factors such as the requirement of large investments, discrepancies in HPAPI banding
New Technologies for HPAPI Manufacturing and Containment
SMI Reports: With new technologies becoming available for the pharmaceutical industry, the HPAPI market is utilising these new innovations to simplify manufacturing processes reducing powder exposure and allowing a semi-continuous production. At this year's HPAPI USA Conference emerging manufacturing technologies will be one of the key points to be discussed along with containment issues, disaster management, Oncology Antibody-Drug Conjugates (ADCs) and staff training procedures. Key highlights include: Alternative HPAPI manufacturing technologies to
The Latest Innovations in HPAPI Manufacturing Technologies
SMi’s inaugural Highly Potent Active Pharmaceutical Ingredients USA Conference, will focus on the latest innovative manufacturing technologies with a special spotlight presentation on effective and safe containment solutions for biologics based HPAPIs, along with cleaning and cross contamination requirements. Keith Jensen, Owner and Consultant at Keith Jensen Consulting, previously at Novartis-MIT Center for Continuous Manufacturing, discusses alternative HPAPI manufacturing technologies to reduce powder exposure and improve safety enabling continuous manufacturing. Other